iRadimed (NASDAQ:IRMD) Stock Price Crosses Above 50 Day Moving Average – What’s Next?

iRadimed Corporation (NASDAQ:IRMD) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $100.44 and traded as high as $102.91. iRadimed shares last traded at $102.80, with a volume of 69,742 shares.

Analysts Set New Price Targets

IRMD has been the topic of several research analyst reports. Roth Mkm reaffirmed a “buy” rating and set a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. Lake Street Capital reissued a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a report on Wednesday, February 11th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $120.00.

iRadimed Stock Up 1.1%

The stock has a market cap of $1.31 billion, a P/E ratio of 58.74 and a beta of 1.12. The firm’s 50 day simple moving average is $100.44 and its two-hundred day simple moving average is $89.15.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The company had revenue of $22.69 million for the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. As a group, equities analysts predict that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were issued a $0.20 dividend. This is an increase from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Monday, February 23rd. iRadimed’s dividend payout ratio is 45.71%.

Insider Activity at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $100.04, for a total transaction of $500,200.00. Following the sale, the chief executive officer directly owned 2,250,000 shares in the company, valued at approximately $225,090,000. This represents a 0.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 32,500 shares of company stock worth $3,222,125 over the last three months. 36.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IRMD. T. Rowe Price Investment Management Inc. increased its stake in shares of iRadimed by 410.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after purchasing an additional 205,783 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of iRadimed by 37.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock worth $19,964,000 after buying an additional 55,426 shares during the period. Informed Momentum Co LLC bought a new position in iRadimed in the 4th quarter worth approximately $5,361,000. SG Americas Securities LLC grew its holdings in iRadimed by 88.6% in the 4th quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after buying an additional 33,072 shares in the last quarter. Finally, Invesco Ltd. increased its position in iRadimed by 473.9% in the 4th quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock valued at $3,418,000 after acquiring an additional 29,010 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.